Influenza NA Inhibitor Market by Product Type and Application- Global Industry Analysis & Forecast to 2027
Published On : October 2020 Pages : 152 Category: Pharma & Healthcare Report Code : HC1013176
Influenza NA Inhibitor Market By Product Type (Zanamivir, Oseltamivir, Peramivir) and Application (Influenza A Treatment, Influenza B Treatment)- Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Influenza NA Inhibitor Markethas encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.Influenza NA Inhibitor is an antiviral drugthat block the function of viral neuraminidases of the influenza virus, by preventing its reproduction by budding from the host cell.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global Influenza NA Inhibitor Marketand estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Turkey
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Green Cross
- NeoPharm
- Henan DaKen Chemical
- Roche
- Shionogi Co.
- GlaxoSmithKline
- Chemwill Asia Co.,Ltd.
- ATK Chemical
- Moksha8 Pharma
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Influenza NA Inhibitor Market, By Product Type, Estimates and Forecast, 2017-2027 ($Million)
o Zanamivir
o Oseltamivir
o Peramivir
· Influenza NA Inhibitor Market, ByApplication, Estimates and Forecast, 2017-2027 ($Million)
o Influenza A Treatment
o Influenza B Treatment
· Influenza NA Inhibitor Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Green Cross
o NeoPharm
o Henan DaKen Chemical
o Roche
o Shionogi Co.
o GlaxoSmithKline
o Chemwill Asia Co.,Ltd.
o ATK Chemical
o Moksha8 Pharma
· Influenza NA Inhibitor Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Influenza NA Inhibitor Market , By Country
o U.S. Influenza NA Inhibitor Market
o Canada Influenza NA Inhibitor Market
o Mexico Influenza NA Inhibitor Market
o Europe
§ Europe Influenza NA Inhibitor Market , By Country
o UK Influenza NA Inhibitor Market
o Germany Influenza NA Inhibitor Market
o France Influenza NA Inhibitor Market
o Russia Influenza NA Inhibitor Market
o Italy Influenza NA Inhibitor Market
o Rest of Europe Influenza NA Inhibitor Market
o Asia-Pacific
§ Asia-Pacific Influenza NA Inhibitor Market , By Country
o China Influenza NA Inhibitor Market
o Japan Influenza NA Inhibitor Market
o South Korea Influenza NA Inhibitor Market
o India Influenza NA Inhibitor Market
o Southeast Asia Influenza NA Inhibitor Market
o Rest of Asia-Pacific Influenza NA Inhibitor Market
o South America
§ South America Influenza NA Inhibitor Market
o Brazil Influenza NA Inhibitor Market
o Argentina Influenza NA Inhibitor Market
o Columbia Influenza NA Inhibitor Market
o Rest of South America Influenza NA Inhibitor Market
o Middle East and Africa
§ Middle East and Africa Influenza NA Inhibitor Market
o Saudi Arabia Influenza NA Inhibitor Market
o UAE Influenza NA Inhibitor Market
o Egypt Influenza NA Inhibitor Market
o Nigeria Influenza NA Inhibitor Market
o South Africa Influenza NA Inhibitor Market
o TurkeyInfluenza NA Inhibitor Market
o Rest of MEA Influenza NA Inhibitor Market
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Influenza NA Inhibitor Market, By Product Type
5.1. Introduction
5.2. Global Influenza NA Inhibitor Revenue and Market Share by Product Type (2017-2021)
5.2.1. Global Influenza NA Inhibitor Revenue and Revenue Share by Product Type (2017-2021)
5.3. Zanamivir
5.3.1. Global Zanamivir Revenue and Growth Rate (2017-2021)
5.4. Oseltamivir
5.4.1. Global Oseltamivir Revenue and Growth Rate (2017-2021)
5.5. Peramivir
5.5.1. Global Peramivir Revenue and Growth Rate (2017-2021)
6. Influenza NA Inhibitor Market, By Applications
6.1. Introduction
6.2. Global Influenza NA Inhibitor Revenue and Market Share by Applications (2017-2021)
6.2.1. Global Influenza NA Inhibitor Revenue and Revenue Share by Applications (2017-2021)
6.3. Influenza A Treatment
6.3.1. Global Influenza A Treatment Revenue and Growth Rate (2017-2021)
6.4. Influenza B Treatment
6.4.1. Global Influenza B Treatment Revenue and Growth Rate (2017-2021)
7. Influenza NA Inhibitor Market, By Region
7.1. Introduction
7.2. Global Influenza NA Inhibitor Revenue and Market Share by Regions
7.2.1. Global Influenza NA Inhibitor Revenue by Regions (2017-2021)
7.3. North America Influenza NA Inhibitor by Countries
7.3.1. North America Influenza NA Inhibitor Revenue and Growth Rate (2017-2021)
7.3.2. North America Influenza NA Inhibitor Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Influenza NA Inhibitor by Countries
7.4.1. Europe Influenza NA Inhibitor Revenue and Growth Rate (2017-2021)
7.4.2. Europe Influenza NA Inhibitor Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Influenza NA Inhibitor by Countries
7.5.1. Asia-Pacific Influenza NA Inhibitor Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Influenza NA Inhibitor Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Influenza NA Inhibitor by Countries
7.6.1. South America Influenza NA Inhibitor Revenue and Growth Rate (2017-2021)
7.6.2. South America Influenza NA Inhibitor Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Influenza NA Inhibitor by Countries
7.7.1. Middle East and Africa Influenza NA Inhibitor Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Influenza NA Inhibitor Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. Green Cross
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. NeoPharm
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Henan DaKen Chemical
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Roche
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Shionogi Co.
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. GlaxoSmithKline
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Chemwill Asia Co.,Ltd.
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. ATK Chemical
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Moksha8 Pharma
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
9. Influenza NA Inhibitor Market Forecast (2022-2027)
9.1. Global Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Influenza NA Inhibitor Market Forecast by Regions (2022-2027)
9.2.1. North America Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.1.1. United States Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.1.2. Canada Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.1.3. Mexico Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.2. Europe Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.2.1. Germany Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.2.2. France Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.2.3. UK Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.2.4. Russia Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.2.5. Italy Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.3. Asia-Pacific Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.3.1. China Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.3.2. Japan Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.3.3. Korea Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.3.4. India Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.4. South America Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.4.1. Brazil Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.4.2. Argentina Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.4.3. Columbia Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.4.4. Rest of South America Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.5. Middle East and Africa Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.5.3. Egypt Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.5.4. Nigeria Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.5.5. South Africa Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.5.6. Turkey Influenza NA Inhibitor Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Influenza NA Inhibitor Market Forecast (2022-2027)
9.3. Influenza NA Inhibitor Market Forecast by Product Type (2022-2027)
9.3.1. Influenza NA Inhibitor Forecast by Product Type (2022-2027)
9.3.2. Influenza NA Inhibitor Market Share Forecast by Product Type (2022-2027)
9.4. Influenza NA Inhibitor Market Forecast by Applications (2022-2027)
9.4.1. Influenza NA Inhibitor Forecast by Applications (2022-2027)
9.4.2. Influenza NA Inhibitor Market Share Forecast by Applications (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Influenza NA Inhibitor Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Influenza NA Inhibitor Revenue and Revenue Share by Product Type (2017-2019)
Figure Global Zanamivir Revenue and Growth Rate (2017-2019)
Figure Global Oseltamivir Revenue and Growth Rate (2017-2019)
Figure Global Peramivir Revenue and Growth Rate (2017-2019)
Table Global Influenza NA Inhibitor Revenue and Revenue Share by Applications (2017-2019)
Figure Global Influenza A Treatment Revenue and Growth Rate (2017-2019)
Figure Global Influenza B Treatment Revenue and Growth Rate (2017-2019)
Table Global Influenza NA Inhibitor Revenue by Regions (2017-2019)
Figure North America Influenza NA Inhibitor Growth Rate (2017-2019)
Figure North America Influenza NA Inhibitor Revenue and Growth Rate (2017-2019)
Figure North America Influenza NA Inhibitor by Countries (2017-2019)
Figure North America Influenza NA Inhibitor Revenue (Million USD) by Countries (2017-2019)
Figure United States Influenza NA Inhibitor Growth Rate (2017-2019)
Figure United States Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Canada Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Mexico Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Europe Influenza NA Inhibitor Revenue and Growth Rate (2017-2019)
Figure Europe Influenza NA Inhibitor by Countries (2017-2019)
Figure Europe Influenza NA Inhibitor Revenue (Million USD) by Countries (2017-2019)
Figure Germany Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Germany Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Influenza NA Inhibitor Growth Rate (2017-2019)
Figure France Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Influenza NA Inhibitor Growth Rate (2017-2019)
Figure UK Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Russia Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Italy Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Rest of Europe Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Asia-Pacific Influenza NA Inhibitor Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Influenza NA Inhibitor by Countries (2017-2019)
Figure Asia-Pacific Influenza NA Inhibitor Revenue (Million USD) by Countries (2017-2019)
Figure China Influenza NA Inhibitor Growth Rate (2017-2019)
Figure China Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Japan Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Korea Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Influenza NA Inhibitor Growth Rate (2017-2019)
Figure India Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Southeast Asia Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Influenza NA Inhibitor Growth Rate (2017-2019)
Figure South America Influenza NA Inhibitor Revenue and Growth Rate (2017-2019)
Figure South America Influenza NA Inhibitor by Countries (2017-2019)
Figure South America Influenza NA Inhibitor Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Brazil Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Argentina Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Columbia Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Rest of South America Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Middle East and Africa Influenza NA Inhibitor Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Influenza NA Inhibitor by Countries (2017-2019)
Figure Middle East and Africa Influenza NA Inhibitor Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Saudi Arabia Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Influenza NA Inhibitor Growth Rate (2017-2019)
Figure United Arab Emirates Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Egypt Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Nigeria Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Influenza NA Inhibitor Growth Rate (2017-2019)
Figure South Africa Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Turkey Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Influenza NA Inhibitor Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2017-2019)
Table Green Cross Influenza NA Inhibitor Financial Overview
Table NeoPharm Influenza NA Inhibitor Financial Overview
Table Henan DaKen Chemical Influenza NA Inhibitor Financial Overview
Table Roche Influenza NA Inhibitor Financial Overview
Table Shionogi Co. Influenza NA Inhibitor Financial Overview
Table GlaxoSmithKline Influenza NA Inhibitor Financial Overview
Table Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Financial Overview
Table ATK Chemical Influenza NA Inhibitor Financial Overview
Table Moksha8 Pharma Influenza NA Inhibitor Financial Overview
Figure Global Influenza NA Inhibitor Revenue (Millions USD) and Growth Rate (2019-2027)
Table Influenza NA Inhibitor Market Forecast by Regions (2019-2027)
Figure North America Influenza NA Inhibitor Market Forecast (2019-2027)
Figure United States Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Canada Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Mexico Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Europe Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Germany Influenza NA Inhibitor Market Forecast (2019-2027)
Figure France Influenza NA Inhibitor Market Forecast (2019-2027)
Figure UK Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Russia Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Italy Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Rest of Europe Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Asia-Pacific Influenza NA Inhibitor Market Forecast (2019-2027)
Figure China Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Japan Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Korea Influenza NA Inhibitor Market Forecast (2019-2027)
Figure India Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Southeast Asia Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Influenza NA Inhibitor Market Forecast (2019-2027)
Figure South America Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Brazil Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Argentina Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Columbia Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Rest of South America Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Middle East and Africa Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Saudi Arabia Influenza NA Inhibitor Market Forecast (2019-2027)
Figure United Arab Emirates Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Egypt Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Nigeria Influenza NA Inhibitor Market Forecast (2019-2027)
Figure South Africa Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Turkey Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Influenza NA Inhibitor Market Forecast (2019-2027)
Figure Global Influenza NA Inhibitor Forecast by Product Type (2019-2027)
Figure Global Influenza NA Inhibitor Market Share Forecast by Product Type (2019-2027)
Figure Global Influenza NA Inhibitor Forecast by Product Type (2019-2027)
Figure Global Influenza NA Inhibitor Forecast by Applications (2019-2027)
Figure Global Influenza NA Inhibitor Market Share Forecast by Applications (2019-2027)
Figure Global Influenza NA Inhibitor Forecast by Applications (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|